Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ic/II Clinical Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of Multiple Oral Doses of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa

NCT06932003 is registered in ClinicalTrials.gov with Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. as lead sponsor.

NCT NCT06932003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06932003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ic/II Clinical Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of Multiple Oral Doses of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
Lead sponsor
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 8, 2025
Completion date
December 30, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)